BAFNAPHPharmaceuticals
Bafna Pharmaceuticals Ltd — PE Ratio & Valuation Analysis
₹109.34
-4.38%
Current P/E34.53xPrice to earnings
Industry P/E31.77xSector average
4Y Avg P/E44.0x21.5% below avg
⚠️
8.7% Premium to Industry
BAFNAPH P/E 34.53x vs sector avg 31.77x
📊
Historical PE Ratio
| Year | EPS (₹) | Year-end Price | PE Ratio |
|---|---|---|---|
| 2025 | ₹1.76 | ₹151 | 85.6x |
| 2024 | ₹3.11 | ₹79 | 25.4x |
| 2023 | ₹4.79 | ₹92 | 19.2x |
| 2022 | ₹2.21 | ₹101 | 45.7x |
PE = Year-end closing price ÷ Diluted EPS. Source: NSE/BSE filings.
💡
Understanding Bafna Pharmaceuticals Ltd Valuation
Bafna Pharmaceuticals Ltd (BAFNAPH) currently trades at 34.53x earnings. The Pharmaceuticals sector average PE is 31.77x. BAFNAPH commands a premium, reflecting high growth expectations. Historically, BAFNAPH has traded at an average PE of 44.0x — it is currently below that level. Always evaluate PE alongside earnings growth (PEG ratio), return on equity, debt levels and business quality. A lower PE isn't always better. Educational data only — not investment advice.
ROE
7.69%
Dividend Yield
0.00%
More on Bafna Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.